Related Experiment Video

Updated: Jul 5, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment

B Spänkuch1, K Strebhardt

  • 1Department of Obstetrics and Gynecology, Medical School, J.W. Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. Birgit.Spaenkuch@t-online.de

Current Pharmaceutical Design
|May 14, 2008
PubMed

Insights

Molecular-targeted cancer drugs offer improved efficacy and reduced toxicity. Combining these with gene silencing strategies like antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) can overcome chemotherapy resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Cancer drug development has shifted from non-specific cytotoxic agents to specific molecular-targeted therapies.
  • Targeted agents demonstrate improved cancer cell selectivity, enhanced anti-tumor efficacy, and reduced toxicity compared to traditional chemotherapy.
  • Chemotherapy resistance remains a significant challenge in cancer treatment, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To explore the potential of gene silencing using antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to overcome cancer drug resistance.
  • To evaluate the synergistic effects of combining nucleic acid-based agents with anti-neoplastic drugs for improved cancer therapy.
  • To investigate strategies for sensitizing resistant cancer cells to conventional chemotherapeutic agents.

Main Methods:

  • Utilizing antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to specifically down-regulate the expression of cancer-relevant genes.
  • Investigating the combination of nucleic acid-based agents with existing anti-neoplastic drugs.
  • Assessing the impact of these combined strategies on cell cycle arrest, apoptosis, cell proliferation, and tumor growth in vitro and in vivo.

Main Results:

  • Gene silencing via ASOs and siRNAs presents a promising strategy to reduce cancer cell resistance.
  • Combination therapies involving nucleic acid agents and anti-neoplastic drugs can induce synergistic anti-cancer effects.
  • These combined approaches show potential for enhancing therapeutic regimens and re-sensitizing resistant cancer cells.

Conclusions:

  • The development of molecular-targeted cancer drugs represents a significant advancement in oncology.
  • Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) offer targeted gene silencing capabilities to combat chemotherapy resistance.
  • Combination strategies hold promise for improving current cancer treatment protocols and overcoming drug resistance.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...